Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

6 results
5:53 PM, Jul 24, 2013  |  BC Extra | Financial News

Heat Biologics off in trading debut

using Heat Biologics' Immune Pan-Antigen Cytotoxic Therapy (ImPACT) technology to secrete antigens bound to a heat shock 90 kDa protein beta 1
5:52 PM, Jul 23, 2013  |  BC Extra | Financial News

Heat Biologics raises $25 million in IPO

using Heat Biologics' Immune Pan-Antigen Cytotoxic Therapy (ImPACT) technology to secrete antigens bound to a heat shock 90 kDa protein beta 1
4:34 PM, Jul 08, 2013  |  BC Extra | Financial News

Heat Biologics bumps up share number for IPO

using Heat Biologics' Immune Pan-Antigen Cytotoxic Therapy (ImPACT) technology to secrete antigens bound to a heat shock 90 kDa protein beta 1
6:46 PM, May 30, 2013  |  BC Extra | Financial News

Heat Biologics sets IPO range

using Heat Biologics' Immune Pan-Antigen Cytotoxic Therapy (ImPACT) technology to secrete antigens bound to a heat shock 90 kDa protein beta 1
5:13 PM, May 06, 2013  |  BC Extra | Financial News

Heat Biologics files for IPO

NSCLC). HS-110 is a transplant of patient lung cancer cells engineered to express and secrete heat shock 90 kDa protein beta 1
12:00 AM, Jan 23, 2003  |  BC Extra | Financial News

Antigenics raises $62 million

AGEN to an existing shareholder. The deal has a 518,000-share overallotment. AGEN's Oncophage autologous tumor-derived gp96